---
title: "Obefazimod (ABX464) in Ulcerative colitis: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Clinical presentation - signs and symptoms. Topics: Intestinal symptoms: bloody diarrhea, rectal bleeding, urgency, and tenesmus; Systemic symptoms: abdominal pain, weight loss, and fatigue; Severe disease: fulminant colitis, toxic megacolon, and Truelove and Witts criteria; Flares and bowel frequency: patient survey in 10 countries; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Intestinal symptoms: bloody diarrhea, rectal bleeding, urgency, and tenesmus

> “Patients usually present with bloody diarrhoea, and the diagnosis is based on a combination of clinical, biological, endoscopic, and histological findings.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “UC impairs quality of life secondary to inflammation of the colon causing chronic diarrhea and rectal bleeding.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “The initial presentation of new UC is usually characterized by symptoms of an inflamed rectum that include bleeding, urgency, and tenesmus (a sense of pressure).”
> “The primary symptoms assessed include frequency of bowel movements, including number of nocturnal bowel movements, and rectal bleeding as the proportion of bowel movements that are mixed with visible blood. Other important symptoms to assess include bowel urgency, abdominal pain, bowel cramping, and weight loss, which can be a marker of severity of disease.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.6-2"></a>

### Systemic symptoms: abdominal pain, weight loss, and fatigue

> “Symptoms may include frequent diarrhea, sometimes with blood or pus, abdominal and/or rectal pain, weight loss, and fatigue.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

> “In the Manitoba cohort, patients with UC reported high rates of fatigue and sleep difficulties, particularly those with active symptoms (67% and 72%, respectively), as compared to those with inactive UC (30% and 57%, respectively), and these rates were not significantly different than in patients with CD (51).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.6-3"></a>

### Severe disease: fulminant colitis, toxic megacolon, and Truelove and Witts criteria

> “Mild colitis is defined as fewer than 4 bowel movements daily, normal temperature, heart rate, hemoglobin (>11 g/dL), and ESR (<20 mm/hr). Severe disease is defined by bowel frequency greater than 6 times a day in conjunction with fever, tachycardia, anemia, or an elevation in ESR.”
> “The absolute indications for surgery in ASUC include toxic megacolon, perforation, uncontrolled severe hematochezia, or multiorgan dysfunction (311).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.6-4"></a>

### Flares and bowel frequency: patient survey in 10 countries

> “A high proportion (87%) of patients reported having experienced a flare in the past year, with an average of 4.3 flares (SD, 7.4) experienced.”
> “Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.”
> “Patients typically experienced initial symptoms at a mean age of 30.0 years (standard deviation [SD], 12.7; median, 29) and were diagnosed with UC at a mean age of 32.0 years (SD, 12.2; median, 30; Table 1).”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="topic-2.2.1.6-5"></a>

### Extraintestinal manifestations: joint, skin, ocular, oral, and hepatobiliary

> “In addition, a thorough history should assess the presence of extraintestinal manifestations including joint pain or swelling, skin eruptions or inflammatory lesions, ocular inflammation, oral manifestations including mouth sores and angular cheilitis, and symptoms suggesting hepatobiliary involvement such as jaundice or pruritus.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “A number of extraintestinal manifestations (EIMs) have also been associated with UC, including musculoskeletal, ocular, dermatologic, hepatobiliary, and psychological effects.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

> “Extraintestinal manifestations, such as primary sclerosing cholangitis, occur in approximately 27% of patients with UC.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.6-6"></a>

### Psychological symptoms: anxiety and depression with active disease

> “Patients with active disease are more likely to have comorbid psychological conditions of anxiety and depression and are more likely to have impaired social interactions or career progression (8).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
